Scroll to top
© 2020, Startuprecipe theme by Rssow

/DISREGARD RELEASE: Antengene Corporation Limited/

We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.

Related News

Access to the latest Korean startup news and startup database for free

sign up for Startup Recipe newsletter